<DOC>
	<DOCNO>NCT02817425</DOCNO>
	<brief_summary>This study design compare three chemotherapy regimen ( TEGAFOX Sequential S-1 SOX Sequential S-1 SOX non-Sequential S-1 ) postoperative patient gastric cancer , observe record efficacy tolerance , evaluate regimen well .</brief_summary>
	<brief_title>A Efficacy Tolerability Study TEGAFOX Sequential S-1 Treatment Adjuvant Chemotherapy Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>75≧Age≧18 Histologically cytologically confirm gastrointestinal cancer Stage Ⅱ Ⅲ Ⅳ ECOG ≦2 Accept gastric cancer radical resection Life expectancy least three month Written inform consent participate trial History severe hypersensitivity reaction ingredient S1\TF\5FU/calcium folinate oxaliplatin Inadequate hematopoietic function define : white blood cell ( WBC ) less 5x10^9/L absolute neutrophil count ( ANC ) less 2x10^9/L platelet less 100*10^9/L Inadequate hepatic renal function define : serum bilirubin great 2 time upper limit normal range alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) great 2.5 time ULN demonstrable liver metastasis great 5 time ULN presence liver metastases blood creatinine level great 2 time ULN Presence peripheral neuropathy Receiving concomitant treatment fluoropyrimidine drug flucytosine drug Women pregnant lactate fertile woman childbearing potential unless use reliable appropriate contraceptive method throughout treatment period ( Including male ) Psychiatric disorder symptom make participation patient difficult ; Concomitant illness might aggregate active , noncontrolled disease congestive heart failure , ischemic heart disease , uncontrolled hypertension arrhythmia six month Severe complication ( ) , e.g. , paresis intestine , ileus , radiographically confirm interstitial pneumonitis pulmonary fibrosis , glomerulonephritis , renal failure , poorlycontrolled diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>S-1</keyword>
	<keyword>Adjuvant Chemotherapy</keyword>
	<keyword>TEGAFOX</keyword>
</DOC>